A newly developed blood test screens for biomarkers associated with anxiety to determine a person's risk of developing the disorder as well as monitor the severity of symptoms in those with anxiety.
A new blood-based test to screen for biomarkers of glioblastoma brain cancer has been developed by researchers at Penn State. The test looks for elevated levels of IL13Rα2, an antigen receptor that is derived from glioblastoma tumors.
Researchers have developed a new blood test for brain-derived Tau that can follow and track the progression of Alzheimer's disease while excluding other dementias.
A newly developed blood test can detect brain-derived tau (BD-tau), a biomarker of Alzheimer's disease neurodegeneration.
The levels of two protein biomarkers, GFAP and UCH-L1 found in blood samples taken 24 hours after a traumatic brain injury can help to predict which patients will die and which will obtain a severe disability.
A newly developed immuno-infrared sensor allowed researchers to discover biomarkers for Alzheimer's disease in blood samples 17 years before clinical symptoms appeared. The sensory is able to detect the misfolding of amyloid beta.
Researchers have identified a blood biomarker that predicts the risk of suicide in patients with major depressive disorder. The biomarker also can help researchers understand the molecular changes in suicide victims.
The discovery of a unique ratio of metabolites in blood samples taken from early-stage Alzheimer's patients could be a critical new biomarker for early detection of the neurodegenerative disease.
NfL, a single biomarker in the blood, can accurately predict the presence of underlying neurodegenerative disorders, such as FTD and ALS, in people with cognitive problems.
A new blood test can distinguish the severity of a person's depression and their risk for developing severe depression at a later point. The test can also determine if a person is at risk for developing bipolar disorder. Researchers say the blood test can also assist in tailoring individual options for therapeutic interventions.
Blood samples taken from people enrolled in an Alzheimer's research study revealed higher levels of phosphorylated tau 217 that correlated with the presence of amyloid plaques. People with amyloid in their brains had up to three times more of the tau protein in their blood than those who had no evidence of amyloid accumulation. The higher levels of the protein were evident even in people with no signs of cognitive decline.
New evidence confirms COVID-19 infection is the cause of the Kawasaki-like syndrome affecting children.
